

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): March 29, 2024

**BioCorRx Inc.**

(Exact name of registrant as specified in its charter)

|  |   |   |
|--|---|---|
| <u>Nevada</u><br>(State or other jurisdiction<br>of incorporation) | <u>000-54208</u><br>(Commission<br>File Number) | <u>90-0967447</u><br>(IRS Employer<br>Identification No.) |
|--|---|---|

**2390 East Oranewood Avenue, Suite 500**  
**Anaheim, CA 92806**  
(Address of principal executive offices) (Zip Code)

**(714) 462-4880**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of each class</u> | <u>Trading<br/>Symbol(s)</u> | <u>Name of each exchange<br/>on which registered</u> |
|----------------------------|------------------------------|--|
| N/A                        | N/A                          | N/A  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Resignation of Directors*

On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “Board”) of BioCorRx Inc. (the “Company”), effective March 31, 2024 (the “Granier Resignation”).

Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “Murthy Resignation”).

The Granier Resignation and Murthy Resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals, a subsidiary of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**BioCorRx Inc.**

Date: April 3, 2024

By: /s/ Lourdes Felix  
Lourdes Felix  
Chief Executive Officer